Results 291 to 300 of about 219,337 (367)

Management of von Willebrand Disease With a Factor VIII-Poor von Willebrand Factor Concentrate: Results From the Paediatric Cohort of a Prospective Observational Post-Marketing Study. [PDF]

Haemophilia
Goudemand J, Borel-Derlon A, Claeyssens S, Chambost H, Mourey G, Harroche A, Meunier S, Henriet C, Leroi T, Susen S, Repesse Y.   +10 more
europepmc   +1 more source

The molecular linkage of von Willebrand Factor (VWF) and pathological coagulation in disease [PDF]

Shengshi Huang
openalex   +1 more source

The Calcium‐Binding Protein S100A10 (p11) Is Required for Normal Motor Performance by Regulating Vesicle Dynamics at Excitatory Synapses

Acta Physiologica, Volume 242, Issue 2, February 2026.
ABSTRACT Aim Identifying interactors in sensorimotor processing and neurotransmission remains a current challenge for understanding neural information processing and brain function. Methods To evaluate the role of p11 in sensorimotor processing and excitatory synaptic neurotransmission, neuron‐specific lentivirus‐directed p11 silencing, small ...
Esther Vilches‐Herrando, Guillermo Rodríguez‐Bey, Rosendo G. Hernández, Ángela Gento‐Caro, Ángel M. Pastor, Antonio Campos‐Caro, David González‐Forero, Bernardo Moreno‐López   +7 more
wiley   +1 more source

Soluble cell adhesion molecules and von Willebrand factor in children with Kawasaki disease

, 1995
Margot Nash, V Shah, Michael J. Dillon
openalex   +2 more sources

Avascular Necrosis and Minimal Trauma Fractures in Telomere Biology Disorders

Clinical Genetics, Volume 109, Issue 2, Page 286-293, February 2026.
Avascular Necrosis (AVN) and Minimal Trauma Fractures (MTF) cause significant morbidity in people with Telomere Biology Disorders (TBDs). They occur more frequently in young patients and in those with autosomal recessive (AR) or X‐linked recessive (XLR) than in autosomal dominant (AD) genotypes.
Arman M. Niknafs, Neelam Giri, Marena R. Niewisch, Sharon A. Savage   +3 more
wiley   +1 more source

Probing rare von Willebrand disease-causing mutations in the D4 and C-domains of von Willebrand factor. [PDF]

Res Pract Thromb Haemost
Mobayen G, El-Mansi S, Chion A, Nightingale TD, McKinnon TAJ.   +4 more
europepmc   +1 more source

T‐Cell–Redirecting Immunotherapies in Relapsed/Refractory Mantle Cell Lymphoma: Current Evidence, Sequencing, and Future Directions

European Journal of Haematology, Volume 116, Issue 2, Page 129-141, February 2026.
ABSTRACT Relapsed/refractory (R/R) mantle cell lymphoma (MCL) remains a therapeutic challenge, particularly in patients with high‐risk features or prior exposure to Bruton's tyrosine kinase inhibitors (BTKis). The advent of T‐cell–redirecting immunotherapies, including chimeric antigen receptor T‐cell (CAR‐T) therapy and bispecific antibodies (BsAbs ...
Santino Caserta, Enrica Antonia Martino, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Fortunato Morabito, Massimo Gentile   +10 more
wiley   +1 more source

Corrigendum to 'Deep molecular modeling and mechanistic insights into type 2A von Willebrand disease with von Willebrand factor A2 domain mutations': [Research and Practice in Thrombosis and Haemostasis 9(7) (2025) 103233]. [PDF]

Res Pract Thromb Haemost
Seidizadeh O, Mollica L, Giana D, Baronciani L, Colpani P, Sicuro L, Cairo A, Peyvandi F.   +7 more
europepmc   +1 more source